ANDA 213146, held by Pharmobedient. Deferasirox.
As of Nov 15, 2026, ANDA 213146 (Deferasirox), held by Pharmobedient, was first approved by FDA on May 3, 2024, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 3, 2024 | Original application | Approved | None posted |
| Deferasirox90MG · granule;oral | Deferasirox | Discontinued |
| Deferasirox180MG · granule;oral | Deferasirox | Discontinued |
| Deferasirox360MG · granule;oral | Deferasirox | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
